Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Diagnostic devices sits at the center of this question for families navigating dementia.
Over the past year, the Alzheimer’s disease diagnostic landscape has shifted fundamentally. Two new blood tests—one approved by the FDA in May 2025 and another in October 2025—now offer patients a far less invasive way to get answers about cognitive decline. Instead of undergoing a PET brain scan or a lumbar puncture to collect cerebrospinal fluid, patients aged 55 and older with memory or thinking problems can now walk into their doctor’s office, have blood drawn, and receive results that help confirm or rule out Alzheimer’s-related brain changes. For many families navigating the fear and uncertainty of cognitive decline, these tests represent a meaningful shift in how diagnosis actually happens.
What makes these tests different is not just their simplicity—it’s their accuracy and accessibility. The first blood test to be cleared, Lumipulse G, boasts a 91.7% accuracy rate for detecting amyloid plaques in the brain, while Roche’s newer Elecsys pTau181 achieved a 97.9% negative predictive value, meaning it’s exceptionally reliable at ruling out Alzheimer’s pathology when results are negative. The Elecsys test carries particular significance because it’s designed specifically for primary care settings, potentially allowing your regular doctor to identify or exclude Alzheimer’s without sending you to a neurologist or memory clinic. Understanding what these tests can and cannot do—and knowing when they’re right for you—is essential before pursuing diagnosis. This guide walks through the facts patients need to make informed decisions about these emerging diagnostic tools.
Table of Contents
- How Do These FDA-Approved Blood Tests Work?
- Understanding Clinical Performance and What Results Mean
- What Do These Tests Cost?
- How to Access These Tests in Your Doctor’s Office
- Important Limitations and Things to Consider Before Testing
- What Emerging Alzheimer’s Diagnostic Technologies Are on the Horizon?
- What’s Next for Alzheimer’s Diagnosis and Your Role in It?
- Conclusion
How Do FDA-Approved Diagnostic Devices Work?
The two FDA-cleared blood tests detect different biomarkers of Alzheimer’s disease, but both measure proteins that accumulate in the brain during the disease process. The Lumipulse G test, manufactured by Fujirebio and approved on May 16, 2025, measures the ratio of phosphorylated tau-217 and amyloid beta 1-42 in your blood. The Elecsys pTau181 test, created by Roche in collaboration with Eli Lilly and approved on October 13, 2025, focuses specifically on phosphorylated tau-181. Both tests look for evidence of amyloid plaques and tau tangles—the hallmark protein buildup that characterizes Alzheimer’s disease pathology. What’s remarkable about these blood tests is their correlation with brain imaging and cerebrospinal fluid findings. When the Lumipulse G test comes back positive, a PET brain scan or cerebrospinal fluid analysis confirms the presence of amyloid plaques 91.7% of the time.
When it comes back negative, it correctly shows the absence of amyloid pathology 97.3% of the time. The Elecsys pTau181 performs even more impressively on the negative side, correctly ruling out Alzheimer’s pathology in 97.9% of early-stage patients. This reliability is crucial because it means a negative result can genuinely reassure patients and families that Alzheimer’s-related changes are not present. The tests are designed for patients who are already experiencing cognitive symptoms—they’re not screening tools for healthy people. You’re a candidate if you’re 55 or older and have noticed changes in memory, thinking speed, difficulty with language, or other cognitive complaints that concern you or your doctor. The tests aren’t meant to predict future disease in asymptomatic people, and they shouldn’t be used as general wellness blood work. This distinction matters because misunderstanding the intended use could lead to unnecessary testing or misinterpretation of results.
Understanding Clinical Performance and What Results Mean
The clinical data behind these tests is genuinely strong, but it’s important to understand exactly what they measure. These blood tests detect amyloid and tau pathology in the brain—the underlying biological changes that characterize Alzheimer’s disease—but they don’t measure symptoms or cognitive decline directly. You can have positive biomarkers and no symptoms yet (called “preclinical Alzheimer’s”), or you can have cognitive symptoms from other causes with negative biomarkers. The tests are one piece of diagnosis, not the whole picture. When Lumipulse G returns a positive result, it means amyloid plaques are likely present in your brain, but your doctor still needs to assess your cognitive symptoms, history, and other factors to confirm an Alzheimer’s diagnosis.
Similarly, a positive Elecsys pTau181 result indicates tau pathology, which strongly suggests Alzheimer’s-related brain changes but doesn’t define the severity or progression timeline. The strength of these tests is in ruling out Alzheimer’s when results are negative—if your test is negative and you’re experiencing cognitive decline, your doctor can confidently investigate other causes like vitamin B12 deficiency, thyroid disease, depression, or medication side effects. One important limitation: these blood tests have been validated primarily in symptomatic populations, meaning people who already report cognitive complaints. If you take the test and get a positive result, understand that you may not have symptoms now but could develop them over time as the disease progresses. Conversely, some people with Alzheimer’s pathology never develop significant cognitive symptoms during their lifetime—a phenomenon called “preclinical Alzheimer’s disease.” The test tells you about brain pathology, not your future cognitive fate.
What Do These Tests Cost?
Pricing for Alzheimer’s blood tests is evolving as these tests roll out across the healthcare system. According to value-based pricing estimates for 2025-2026, a triage blood test in primary care settings ranges from $220 to $360, with a target price point of $290. If the initial triage test is positive and your doctor wants a confirmatory test, that second test typically costs between $925 and $1,350, with a target value of $1,150. These prices are estimates for what payers and healthcare systems should consider reasonable—actual out-of-pocket costs for patients vary significantly based on insurance coverage, your specific healthcare provider, and your state. The emergence of these tests reflects broader market expansion in Alzheimer’s diagnostics. The global Alzheimer’s disease diagnostics market was valued at $9.94 billion in 2025 and is projected to reach $11.04 billion in 2026, indicating rapid growth and competition among manufacturers.
As more companies develop blood-based Alzheimer’s tests and market competition increases, prices are likely to decline over time. The Elecsys pTau181 test, specifically designed for primary care access, carries the promise of reducing specialist referrals and the associated costs of memory clinic evaluations. Before undergoing testing, ask your doctor about your insurance coverage. Some insurance plans cover these tests under specific circumstances (when cognitive symptoms are documented, when other causes have been ruled out), while others may categorize them as experimental or investigational. Medicare coverage varies by state and by specific test. Your doctor’s office should be able to check your coverage before scheduling the blood draw, potentially saving you from unexpected bills.
How to Access These Tests in Your Doctor’s Office
The primary advantage of the Elecsys pTau181 test is that it’s been cleared for use in primary care settings, meaning your regular internist or family medicine doctor can order it without a neurology referral. You no longer need to navigate the complex process of getting a specialist appointment, which can take weeks or months in many areas. Schedule an appointment with your doctor, discuss your cognitive concerns, and ask whether a blood test for Alzheimer’s biomarkers makes sense for your situation. Your doctor will consider your symptoms, your age, your personal and family history, and whether other causes of cognitive decline have been explored. The Lumipulse G test, while highly accurate, may be more commonly available through memory clinics or neurology practices at this point, though primary care adoption is growing.
If your regular doctor isn’t familiar with these tests yet, you can bring this information to your appointment and ask whether they offer blood-based Alzheimer’s biomarker testing. Many primary care practices are actively adding these tests to their diagnostic toolkit because they improve diagnostic efficiency and reduce the burden on specialist networks. Once your blood is drawn, turnaround time for results is typically 1 to 2 weeks, much faster than scheduling and completing a PET brain scan or lumbar puncture. Your doctor will review results with you and discuss next steps, whether that’s diagnosis confirmation, further evaluation, discussion of medications like aducanumab or lecanemab (which target amyloid pathology), or investigation of alternative causes of your cognitive symptoms. Having results in hand allows for faster clinical decision-making and treatment planning.
Important Limitations and Things to Consider Before Testing
These blood tests are powerful diagnostic tools, but they have real limitations that patients should understand. First, positive results don’t tell you whether your cognitive symptoms are actually caused by Alzheimer’s disease or by something else entirely. Some people have substantial amyloid and tau pathology in their brains but minimal cognitive symptoms, while others have significant cognitive decline from cerebrovascular disease, Lewy body dementia, or frontotemporal dementia—conditions these tests won’t detect. Your doctor needs to integrate blood test results with cognitive testing, brain imaging, and careful history-taking to reach a diagnosis. Second, these tests are designed for symptomatic patients, not for widespread screening of healthy people. If you have no cognitive complaints and no family history of early-onset dementia, these tests are not indicated for you.
Insurance likely won’t cover them, and testing could create unnecessary anxiety without actionable clinical benefit. Similarly, if you’ve had stable cognitive function for years and develop gradual forgetfulness expected with normal aging, that’s different from the cognitive changes these tests are designed to evaluate. Third, a positive test result does not mean your condition is irreversible or that you’ll inevitably progress to dementia. Newer treatments like lecanemab can slow cognitive decline in early Alzheimer’s disease, but only if started early and only in certain disease stages. If your test is positive and your cognitive decline is mild, you may be a candidate for these disease-modifying treatments. Your doctor needs to determine your disease stage and whether you fit criteria for available medications. Conversely, if your decline is severe and advanced, the information from the test may be less actionable, though it still provides diagnostic clarity.
What Emerging Alzheimer’s Diagnostic Technologies Are on the Horizon?
Beyond the two FDA-approved blood tests, the diagnostic pipeline is expanding rapidly. PrecivityAD2, launched by C2N Diagnostics in August 2025, quantifies plasma amyloid beta and tau levels to evaluate Alzheimer’s in patients with cognitive decline—another blood-based option entering the market. In China, BGI Genomics and Roche Diagnostics launched tests in January 2026 designed as auxiliary tools for disease progression assessment, reflecting the global expansion of Alzheimer’s biomarker testing.
These emerging tests will eventually expand diagnostic options and potentially improve accessibility in different healthcare settings. Looking further ahead, companies like InBrain Neurotech are developing ultra-thin graphene implants designed to detect neural signals and deliver targeted electrical brain stimulation. While still experimental, such technologies could one day provide more sophisticated information about brain activity changes in Alzheimer’s disease. These represent the frontier of neurotechnology—not yet available to patients but illustrative of where diagnosis and treatment monitoring may head over the next decade.
What’s Next for Alzheimer’s Diagnosis and Your Role in It?
The approval of blood-based biomarker tests represents a watershed moment in Alzheimer’s diagnosis. What once required specialized brain imaging or invasive lumbar punctures can now be done with a simple blood draw, democratizing access to diagnostic information. This shift empowers primary care doctors to identify Alzheimer’s pathology earlier, when disease-modifying treatments are most likely to help, and to rule out Alzheimer’s quickly so attention can turn to other treatable causes of cognitive decline.
Your role in this evolving landscape is to be informed about what these tests can and cannot do, to have honest conversations with your doctor about your cognitive concerns, and to understand that a positive result is a starting point for treatment discussion, not a death sentence. As more treatments targeting amyloid and tau pathology develop and become available, getting an accurate diagnosis earlier matters more than ever. Stay engaged with your doctor, ask questions about what results mean for your specific situation, and remember that diagnosis is just the beginning of a care plan tailored to your individual needs and circumstances.
Conclusion
The approval of blood-based biomarker tests represents a watershed moment in Alzheimer’s diagnosis. What once required specialized brain imaging or invasive lumbar punctures can now be done with a simple blood draw, democratizing access to diagnostic information. This shift empowers primary care doctors to identify Alzheimer’s pathology earlier, when disease-modifying treatments are most likely to help, and to rule out Alzheimer’s quickly so attention can turn to other treatable causes of cognitive decline.
Your role in this evolving landscape is to be informed about what these tests can and cannot do, to have honest conversations with your doctor about your cognitive concerns, and to understand that a positive result is a starting point for treatment discussion, not a death sentence. As more treatments targeting amyloid and tau pathology develop and become available, getting an accurate diagnosis earlier matters more than ever. Stay engaged with your doctor, ask questions about what results mean for your specific situation, and remember that diagnosis is just the beginning of a care plan tailored to your individual needs and circumstances.
You Might Also Like
- What Families Should Know About Early Alzheimer’s Blood Testing
- Could Urine Tests Become the Next Alzheimer’s Diagnostic Tool?
- Should Adults Ask Their Doctor About Alzheimer’s Blood Testing?
Related reading
- why Alzheimer’s May Be More Complicated Than Amyloid Plaques
- what Does Amyloid Still Mean in Alzheimer’s Research
- why Drugmakers Are Looking Beyond Amyloid for Alzheimer’s Treatments
- could the Next Alzheimer’s Breakthrough Come From Non-Amyloid Targets
- how Tau, Inflammation, and Metabolism Are Changing Alzheimer’s Research
For more on this topic, see Alzheimer’s Association — clinical trials.
